Search results for: Precision Medicine

Should Drug Prices Differ by Indication? The Debate on Indication-based Pricing

11 May 2018

…that the price of a medicine should be linked in some way to the value it generates for patients and the health system is generally accepted. Yet, how can this…

Understanding societal preferences for priority by disease severity in England & Wales

14 November 2024

…gains at almost every level of severity, compared with NICE’s current severity modifier. If NICE seeks to align the value and priority assigned to new medicines and technologies with societal…

The Cost of Drug Shortages

16 September 2024

…off-patent medicines, overlook the risks of drug shortages that those policies may cause, and their potential catastrophic costs. Policymakers should consider this trade-off, in order to promote sustainable drug markets…

Quality of Life in Long-term Cancer Survivors: Implications for Future Health Technology Assessments in Oncology

3 July 2018

…in recent decades due in part to pharmaceutical advances, with a growing range of increasingly effective and targeted medicines being developed, such asimmunotherapies. In the economic modelling of such treatments,…

MoCA Initiative and its Value Framework: An Opportunity to Improve Decision Making for Orphan Drugs in Europe?

18 September 2018

…non-binding, free-of-charge collaboration between stakeholders, created under the European Commission Process on Corporate Responsibility in the Field of Pharmaceuticals. The Medicines Evaluation Committee of the European Social Insurance Platform (…

A Prescription for Green Healthcare Delivery: Insights from an Expert Sustainability Webinar

19 July 2023

…to decision-making. AstraZeneca: From industry, we heard from Matt Shaughnessy, Head of Operations Sustainability at AstraZeneca and Sustainability Lead at the Medicines Manufacturing Industry Partnership. He explains the work that…

Securing Funds for the Proposed NHS Multi-year Funding: The Feasibility of Using a Hypothecated Tax

24 October 2018

…Measurement of Medicines Expenditure in the Context of the 2014-18 PPRS. London: Office of Health Economics.   Sampson, C., O’Neill, P. and Lorgelly, P. (2018) The Impact of New Medicines…

OHE at ISPOR Europe 2018

…medicines, and the approaches to address them. These challenges risk hindering the availability of life-changing treatments for children with rare diseases. Educational symposium: Indication-based Pricing; Who Wins, Who Loses, and…

Approaches, Challenges and Successful Stories of Multi-indication Pricing in Europe

28 November 2018

…The speakers of this HTAi panel session discussed the approaches used to handle the price of medicines with multiple indications in Europe, while also sharing the most important challenges and…